-
Silence TV
View Dr. Klaus Giese's presentation slides here
Silence News
-
29.04.13
-
10.04.13
-
08.03.13
Follow Us On Twitter
>
-
-
RNAi Therapeutics
Silence Therapeutics has created two powerful platforms and a strong pipeline to exploit the Company's impressive technological know-how and IP.
Combined the RNAi and delivery platforms enable the development of multiple products to multiple drug targets allowing the development of novel therapeutics to diseases with high unmet medical need.
Silence Therapeutics wants to capitalise on these, its core competencies, to bring to market the next generation of therapeutic agents (RNAi therapeutics) along-side current small molecule and biological therapies.
J Learn More > -
RNAi Hub
The RNAi Hub is a comprehensive resource for people interested in the latest developments in RNAi Therapeutics. The RNAi Hub regroups in one location the news from the RNAi Therapeutics field, with a particular focus on the following areas of interest:
News Events Presentations Companies Clinical Trials -
07.03.12
Tekmira seeks to dismiss Alnylam’s patent suit alleging siRNA patent infringement
-
29.02.12
Galena Biopharma Announces Expansion of Scientific Advisory Board
-
28.02.12
Galena Biopharma to Present at the Cancer Targets and Therapeutics Conference
-
27.02.12
Galena Biopharma Establishes Record Date for Spin-Off Stock Dividend of RXi Pharmaceuticals Shares
-
Silence Therapeutics AG is a global leader dedicated to the discovery, development and delivery of targeted RNA interference (RNAi) therapeutics for the treatment of serious diseases.
